Enlonstobart

DB21890InvestigationalProtein Based Therapies

Enlonstobart is a recombinant and fully-humanized immunoglobulin G4 monoclonal antibody. It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment... Enlonstobart is currently under investigation in clinical trial NCT06998771 (JSKN003 Combined Treatment of HER2-positive Gastric Cancer).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Code names: SG001 · SYSA1802

Resolves to

Compound

UNIIH533QU433MCAS2651230-53-2

Targets

Q15116PDCD1

What you can answer from here — as of June 26, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

29Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Enlonstobart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account